Last reviewed · How we verify

NCT06812481

Anticholinergic Burden and Osteoporosis in Rheumatoid Arthritis

Recruiting now Last updated 18 September 2025
What this trial tests

trial testing Anticholinergic load was calculated using anticholinergic cognitive load (ACB) in Rheumatoid Arthritis (RA) in 100 participants. Currently enrolling.

Timeline
15 September 2025
Primary endpoint
28 November 2025
31 December 2025

Quick facts

Lead sponsorBalikesir University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date15 September 2025
Primary completion28 November 2025
Estimated completion31 December 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Balikesir University

Who can join

18 and older, any sex, with Rheumatoid Arthritis (RA) or Anticholinergic Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory rheumatological disease. Use of corticosteroids for more than 3 months in RA treatment is considered an important risk factor in terms of developing secondary osteoporosis and increasing the risk of fracture. The cumulative effect of taking one or more drugs with anticholinergic properties is called anticholinergic load. It is stated that anticholinergic load also increases the risk of fracture in individuals. The aim of this study is to investigate the effects of drugs used by patients with Rheumatoid Arthritis (RA) on anticholinergic load and fracture risk. The Fracture Risk Assessment Tool (FRAX) will be used to assess fracture risk in patients. Materials and methods: The study was planned as a prospective cohort study. The study will included 100 patients who were followed up as outpatients with rheumatoid arthritis diagnosis in the physical medicine and rehabilitation clinic between 2024-2025. Patients of both genders and over 18 years of age diagnosed with rheumatoid arthritis will be included in the study. Patients with systemic diseases or medications affecting bone metabolism and those with metallic materials in the hip or lumbar vertebrae affecting bone mineral density measurement will be excluded from the study. Demographic characteristics, systemic diseases, medications used, bone density measurement and blood test values of the patients will be recorded. Patients taking multiple medications with anticholinergic effects create an anticholinergic burden. The Anticholinergic Drug Scale, Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale will be used to measure anticholinergic burden in the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Rheumatoid Arthritis (RA)

Currently open trials in the same condition.

Other Balikesir University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06812481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing